Stephen Hoge - 27 Feb 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ James Dillon, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
27 Feb 2026
Net transactions value
-$995,935
Form type
4
Filing time
03 Mar 2026, 16:14:55 UTC
Previous filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hoge Stephen President C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE /s/ James Dillon, as Attorney-in-Fact 03 Mar 2026 0001760669

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +652 +0.04% 1,458,079 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $16,340 -316 -0.02% $51.71 1,457,763 27 Feb 2026 Direct F2
transaction MRNA Common Stock Options Exercise +611 +0.04% 1,458,374 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $15,306 -296 -0.02% $51.71 1,458,078 27 Feb 2026 Direct F2
transaction MRNA Common Stock Options Exercise +1,436 +0.1% 1,459,514 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $35,938 -695 -0.05% $51.71 1,458,819 27 Feb 2026 Direct F2
transaction MRNA Common Stock Options Exercise +37,131 +2.5% 1,495,950 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $928,350 -17,953 -1.2% $51.71 1,477,997 27 Feb 2026 Direct F2
holding MRNA Common Stock 4,116 27 Feb 2026 By Valhalla, LLC
holding MRNA Common Stock 151,933 27 Feb 2026 By Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -652 -100% $0.000000 0 27 Feb 2026 Common Stock 652 Direct F1, F4
transaction MRNA Restricted Stock Units Options Exercise $0 -611 -20% $0.000000 2,442 27 Feb 2026 Common Stock 611 Direct F1, F5
transaction MRNA Restricted Stock Units Options Exercise $0 -1,436 -11% $0.000000 11,495 27 Feb 2026 Common Stock 1,436 Direct F1, F6
transaction MRNA Restricted Stock Units Options Exercise $0 -37,131 -25% $0.000000 111,393 27 Feb 2026 Common Stock 37,131 Direct F1, F7
transaction MRNA Stock Option (Right to Buy) Award $0 +125,466 $0.000000 125,466 01 Mar 2026 Common Stock 125,466 $53.57 Direct F8
transaction MRNA Restricted Stock Units Award $0 +165,230 $0.000000 165,230 01 Mar 2026 Common Stock 165,230 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F6 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F7 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F8 25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F9 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.